Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLORIA trial.
Melek Güler-YükselMartijn KuijperReinhard BosEsmeralda MolenaarJasper EmmeringSylvia EshuisAdams HumanFloor ReimannMaarten BoersMarc-Redwart KokPublished in: RMD open (2023)
Patients with active RA aged 65+ treated with prednisolone 5 mg/day for 2 years gained about 1 kg in weight, compared with minimal-non-significant-weight loss on placebo. Our data suggest that the small increase in weight is mostly lean mass, rather than increase or redistribution of fat mass traditionally associated with glucocorticoid treatment.
Keyphrases
- placebo controlled
- body weight
- double blind
- body composition
- weight loss
- phase iii
- rheumatoid arthritis
- phase ii
- clinical trial
- study protocol
- low dose
- bone mineral density
- resistance training
- bariatric surgery
- open label
- roux en y gastric bypass
- disease activity
- phase ii study
- physical activity
- gastric bypass
- adipose tissue
- weight gain
- body mass index
- postmenopausal women
- interstitial lung disease
- glycemic control
- skeletal muscle
- fatty acid
- machine learning
- metabolic syndrome
- radiation therapy
- data analysis
- idiopathic pulmonary fibrosis
- type diabetes
- systemic lupus erythematosus
- big data
- rectal cancer
- combination therapy